Japanese encephalitis virus (JEV) is the principal cause of viral encephalitis. The predominance of children among patients with encephalitis in areas where JEV is endemic that do not have immunization programs suggests that acquired immunity is critical in protecting adults against symptomatic JEV encephalitis. We characterized and compared the T cell response to nonstructural (NS) protein 3 between healthy individuals naturally exposed to JEV and patients in the convalescent phase of JEV encephalitis. The NS3 protein, used as a fusion to the 11-amino acid protein transduction domain of human immunodeficiency virus Tat, elicited CD4 + and T helper-dependent CD8 + T cell responses. The production of interferon (IFN)-g by responding T cells was significantly higher in healthy donors than in patients, correlating strongly with acquired protective immunity to JEV. Furthermore, a striking inverse association between IFN-g levels and the severity of postencephalitic sequelae in patients implicated a role of IFN-g in recovery.
Taiwan after childhood immunization using a formalininactivated JEV preparation has been attributed to the induced neutralizing antibodies directed to the structural envelope (E) protein. However their short duration of 4.5 years [1] , in contrast to the 35-year efficacy window of live, attenuated yellow fever virus vaccine [2] , perhaps reflects the inability of the killed vaccine to recruit T cell help. Many reports have documented a role for both CD4 + and CD8 + T cells in controlling experimental murine flaviviral infections [3] [4] [5] [6] [7] [8] . Numerous accounts have identified the flaviviral structural proteins capsid and E and the nonstructural (NS) proteins NS1, NS2a, NS2b, NS3, NS4a, and NS5 as T cell targets in both healthy vaccinated individuals and in individuals with natural infections of yellow fever, dengue, or hepatitis C virus [9] [10] [11] [12] [13] [14] [15] [16] . JEV-directed human T cell responses have, however, been investigated only to E protein, albeit in instances where E protein was made available as the major component of the immunizing preparation [17, 18] and not during natural infection with JEV [19, 20] .
A detailed comparative analysis of T cell responses from healthy, virus-exposed individuals and patients with encephalitis should aid in defining the immune parameters associated with resistance to and recovery from the acute encephalitic phase of infection. That the vast majority of healthy subclinically infected individuals live in areas where JEV is endemic and do not have access to immunization programs offers an attractive model to study the immune parameters that confer resistance against an incessant natural viral challenge. Our earlier studies on T cell responses to the 5 largest among the 10 proteins of JEV in a healthy cohort in an area where JEV was endemic revealed that NS3 was the dominant target of T cells [21] . We report our comparison of T lymphocyte responses to NS3 between nonvaccinated, subclinically infected individuals and convalescent patients residing in the same JEVendemic areas of Southern India.
MATERIALS AND METHODS

Cells and viruses. JEV P20778, West Nile virus E101
, and dengue-2 virus TR 1751 strains (National Center for Cell Science) were propagated in the Aedes albopictus cell line C6/36 at 28ЊC and in Vero cells at 37ЊC in minimal essential medium supplemented with 10% fetal bovine serum (Gibco-BRL).
Generation of recombinant NS3 protein antigen of JEV. The 1857-nt NS3 gene (4608-6464 nt in the JEV genome) was obtained by reverse-transcription polymerase chain reaction of total RNA from JEV P20778-infected C6/36 cells using the Expand RT system (Roche Molecular Biochemicals), and the primer pair 5 -GGATAGAATTCATATGGGGGGCGTGTTT-TGGGACAC-3 (sense) and 5 -GATCCTTATCTCTTCCCTGC-TGCAAAGTCTTT-3 (antisense) was ligated to Klenow-filled XhoI and EcoRI sites of the bacterial expression vector pTat-HA (a gift from Dr. Stephen F. Dowdy, Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri), in frame with the N-terminal 6-histidine leader, 11-aa protein transduction domain (YGRKKRRQRRR) of the HIV Tat protein and a hemagglutinin tag provided by the vector [22] . The recombinant Tat-NS3 fusion protein was purified by electroelution from SDS-polyacrylamide gels, precipitated, and solubilized in PBS. Protein purity was confirmed by N-terminal sequencing using Edman chemistry and the absence of endotoxins using the Pyrogent plus Gel-clot LAL test kit (BioWhittaker). Similarly expressed and purified unrelated green fluorescent protein (Tat-GFP) was used as the control antigen.
Study subjects. Peripheral blood samples were obtained between June and August 2002 from 2 test and 1 control group of individuals at the district hospital, Vijayanagar Institute of Medical Sciences (Bellary, Karnataka, India). Group 1 consisted of 18 healthy, nonvaccinated individuals (aged 5-23 years), with no history of clinical encephalitis but with 11 log 10 plaquereduction neutralization test (PRNT) titer serum antibodies to JEV, which confirmed a prior subclinical infection with JEV. Group 2 consisted of patients with JEV ( , aged 5-22 n p 32 years), sampled 6 months after discharge from the hospital. A diagnosis of JEV infection by hospital authorities was based on clinical symptoms and anti-JEV IgM antibody in the acutephase cerebrospinal fluid (CSF) samples measured by IgM antibody capture (MAC)-ELISA [23] . Flaviviral infections caused by dengue and West Nile virus were ruled out on the basis of the low acute-phase CSF MAC-ELISA titers to these viruses. At the time of sampling, serum PRNTs were additionally performed to reconfirm the diagnosis of JEV encephalitis. Control group 3 had JEV-naive donors chosen on the basis of !0.2 log 10 serum PRNT titers to JEV, dengue virus, and West Nile virus. These included age-matched healthy nonvaccinated volunteers with no history of clinical encephalitis ( ) and patients n p 9 with non-JEV encephalitis who had been discharged 6 months before the date of sampling and who had negative acute-phase CSF MAC-ELISA titers to all 3 flaviviruses ( ). No imn p 9 munosuppressive drugs were administered to any of the patients enrolled in the study. All donors had been vaccinated with Mycobacterium bovis bacille Calmette-Guérin (BCG). Measles, tuberculosis, hepatitis, HIV, and AIDS were all ruled out in the study population. Blood was drawn after written and oral informed consent were obtained from each volunteer or guardian. The protocol and all procedures of the study were conducted in accordance with the ethical guidelines of Indian Council of Medical Research.
JEV-PRNT titers. Serum PRNT titers to JEV were estimated by a modified PRNT-ELISA [24] using JEV-specific hyperimmune mouse ascitic fluid (a kind gift of Dr. Dennis Trent, formerly at Centers for Disease Control and Prevention, Fort Collins, CO) and calculated using the standard formula of the National Institutes of Health, Japan [25] . Dengue virus-and West Nile virus-specific PRNT titer determinations were performed similarly.
Radioimmunoprecipitation (RIP) analysis. Serum antibodies to NS3 were detected by RIP of lysates of 35 S-methionine-labeled JEV-infected Vero cells [20] , and the identity of the NS3 protein was confirmed by Western blotting the immunoprecipitates using JEV-NS3-specific rabbit antiserum.
Protein transduction and immunocytochemistry. Peripheral blood mononuclear cells (PBMCs) were treated with 333 nmol/L recombinant Tat-GFP, Tat-NS3, or wild-type GFP proteins, harvested 3 h later, plated onto poly-l-lysine (Sigma)-coated cover slips, and permeabilized. Then, the intracellular recombinant proteins were detected using specific antiserum and corresponding fluorescein isothiocyanate (FITC)-labeled secondary antibodies. Samples were examined using a Leica DMIRB inverted confocal microscope with the pinhole set at 1.5.
Lymphoproliferation assay. PBMC isolation, antigen stimulation, and lymphoproliferation were performed as described by us elsewhere [21] . Viral antigens included glutaraldehydefixed, JEV-infected Vero cell lysates (VJEs) [20] and purified Tat-NS3 used at the optimal concentration of 50 mg/mL. 
Quantitation of cytokines by ELISA. Quantitative interleukin (IL)-4 and interferon (IFN)-g ELISAs were performed
in triplicate wells with cell culture supernatants collected 48 and 72 h, respectively, after the addition of antigens, using commercially available antibody pairs (Endogen). The limit of detection in these ELISAs was 15 pg/mL.
IFN-g ELISPOT assays.
ELISPOT assays were performed with PBMCs (either CD8 + -depleted or -undepleted) that were stimulated with antigen for 16-18 h at 37ЊC, according to standard procedures [26] . Spots were counted using a stereomicroscope (Carl Zeiss). The highest number of spots obtained without antigen plus 1.96 times the SD of the mean (determined to be 36 cells/10 6 PBMCs) was the cutoff.
Flow cytometry for intracellular molecules.
Anti-CD3 (FITC), anti-CD8/CD4 (phycoerythrin), anti-IFN-g (biotin), anti-CD14 (FITC), and streptavidin Cy-chrome were purchased from BD Pharmingen. Whole-blood cultures were stimulated with Tat-NS3 or Tat-GFP at 50 mg/mL for 6 h at 37ЊC with 3 mmol/L monensin (Sigma) included during the last 4 h, and staining was performed as described elsewhere [27] . For flow cytometric analysis of CD8 + /CD4 + -depleted or reconstituted PBMC, monensin was added during the last 6 h of a 72-h culture with antigen. For each analysis, 20,000-50,000 gated CD3 + CD8/4 hi cells were acquired using a FACScan flow cytometer (Becton Dickinson). Data were analyzed using Winlist software (Verity Software House). Positive staining was affirmed using isotype-matched controls and by comparing the dot plots of cultures stimulated with test and control antigens.
Statistical analysis. Results of lymphoproliferative assays and ELISA are represented as mean SI values and picograms per milliliter, respectively, ‫ע‬SE and compared by the unpaired Student's t test or the nonparametric Mann-Whitney U test, depending on the type of distribution, using GraphPad Prism (version 3.00 for Windows; GraphPad Software). Age and sex trends for SI and IFN-g responses were analyzed using logistic regression and were found not to significantly influence the outcome. Groups being compared were significantly different if . All correlations were quantified using Spearman's P ! .05 rank correlation coefficient.
A scoring system based on clinical status of patients observed during sampling was used to grade postencephalitic neurological deficits, according to severity, as major or minor, as described elsewhere [28] . Major sequelae included grand mal seizures, focal motor convulsions, alkinetic spells, frank mental retardation, hemiplegia/paraplegia/monoplegia, facial palsy, frank motor deficits manifesting as a generalized increase in tone, and lower motor neuron type of weakness. Minor sequelae included scholastic backwardness, subtle neurological abnormalities like rigidity and abnormal posturing, Parkinsonism, ataxia, hearing/speech deficits, and behavioral problems. Minor sequelae were graded as 1, 2, 3, or 4 and major sequelae as 5, 6, 7, or 8 for slight, moderate, considerable, or maximal degree of severity. Complete recovery was assigned a score of 1. Patients with multiple manifestations received cumulative scores as judged by the hospital clinician, who was unaware of the results of the laboratory investigations of immune parameters. Results were decoded and statistically analyzed by a third party who was not involved with any of the investigations. Sequelae were independent of sex or age of patients. Figure 1A depicts 11 log 10 serum PRNT titers to JEV, which established virus exposure in group 1 [1] and in group 2, as expected. JEV PRNT titers of !0.2 log 10 and no detectable antibodies to JEV proteins by RIP (see below) distinguished control group 3. PRNT titers to dengue and West Nile virus were !0.4 and !0.2 log 10 for the 2 test groups and 1 control group, respectively (data not shown).
RESULTS
JEV exposure induces virus-specific humoral and lymphoproliferative responses.
Immunoprecipitation of viral proteins from 35 S-methioninelabeled JEV-infected Vero cell lysates by serum samples from the 2 JEV-seropositive groups detected strong reactions to the 55-kDa E protein (figure 1B). Weaker serum reactivities to a 68-kDa protein (none in P11, figure 1B), identified as NS3 on the basis of Western blotting reactivity to a rabbit JEV-NS3-specific antiserum (figure 1C), as well as to other NS proteins in all JEV-exposed individuals (figure 1B), additionally confirmed natural JEV infection. Control serum samples (group S-methionine-labeled Vero cells immunoprecipitated using serum samples were electrophoresed on SDS-10% polyacrylamide gels, followed by autoradiography. Nos. above the lanes refer to the serial no. of the volunteers. Positions of the envelope (E) and nonstructural (NS) 3 proteins are shown. C, Western blot of the immunoprecipitates shown in panel B with a rabbit JEV-NS3-specific antiserum. D, 3; figure 1B and 1C, lanes C1 and C2) had no reactivity to any viral protein.
All seropositive subjects displayed significant lymphoproliferative response (SI 1 3) to VJEs ( figure 1D) . SI values were 3.2-15.1 among healthy volunteers and 3.0-21.4 among convalescent patients, with comparable means (‫ע‬SE) of 6.68 ‫ע‬ and , respectively ( ; figure 1D) ; these 0.85 7.98 ‫ע‬ 0.69 P p .1197 values corroborated those previously reported in patients with JEV infection [19, 20] . Control PBMCs showed no proliferation to JEV antigens (SI ! 3; mean value, ). 1.21 ‫ע‬ 0.06 The NS3 protein of JEV elicits Th1-type cell-mediated immunity (CMI) responses in healthy, JEV-exposed individuals. After incubation, both Tat-NS3 and Tat-GFP, but not wildtype GFP, were readily detected within PBMCs (figure 2A Tat-NS3 (table 1) Tat-NS3 (mean SI, ; figure 1D ). Thus, 100% of the 1.06 ‫ע‬ 0.05 virus-exposed cohort responded to NS3, which is consistent with previous data that suggested that human JEV-specific T cells primarily targeted NS proteins [19, 20] .
IFN-g is a hallmark of the Th1 responses that are associated with recovery from viral infections. PBMCs from the 18 healthy donors secreted between 300 (HC15) and 4175 (HC18) pg/mL of NS3-specific IFN-g (mean, pg/mL; table 1). Con-1388 ‫ע‬ 218 versely, PBMCs from the 32 convalescent patients secreted surprisingly less IFN-g (mean, pg/mL; range, !15-3794 Table 1 . figure 2B; ), which demonstrated no gen-P 1 .05 eralized inability in convalescent patients to produce IFN-g. IL-4 was indiscernible under the same conditions in either test group, which suggests that NS3 stimulated a predominantly Th1 subtype of T cells. A simultaneous absence of IL-4 and IFN-g was also reported in dengue and hepatitis B virus infections [29, 30] . No IFN-g was produced in response to Tat-GFP in any group and to NS3 in the control group (data not shown), which highlights the specificity of the responses observed.
T cell responses to nonstructural (NS) protein-3 of Japanese encephalitis virus (JEV).
IFN-g-producing, NS3-specific T cells belong to both CD4
+ and CD8 + subsets. Flow cytometry revealed considerable frequencies of IFN-g-positive CD8
+ and CD4 + T cells in Tat-NS3-stimulated whole-blood cultures from healthy donors ( figure  3A) , confirming the potential of this form of soluble antigen to gain access to major histocompatibility complex (MHC) class I and II presentation pathways in vitro. In general, comparable levels of both T cell subsets producing IFN-g were noted in most healthy individuals (range, 0.17%-1.63% CD8 + cells and 0.02%-2.59% CD4 + cells; + cells significantly reduced the frequency of total IFNg-producing cells in 8 of 12 individuals analyzed by ELISPOT, with a total abolition of spots in HC8 (figure 3B). No reduction in frequencies occurred in HC5 and HC11, whose flow cytometry data revealed only CD4 + T cells producing this cytokine. CD8 + T cells specific to NS3 are CD4 + T cell dependent. We then asked whether the CD8 + or CD4 + T cell subset was required for Tat-NS3-stimulated IFN-g production by the other. The depletion of CD4 + cells from PBMCs from 2 healthy JEV-exposed donors almost completely abrogated IFN-g production from CD8 + T cells, despite prolonging the period of culture to 72 h (figure 4). In contrast, the depletion of CD8 + cells before culture with antigen had little effect on IFN-g production by CD4 + T cells. The reconstitution of CD8-depleted PBMCs with purified CD8 + cells before antigenic stimulation resulted in cytokine production by both T cell subsets. The measurement of supernatant IFN-g confirmed these results (figure 4). Comparable frequencies of CD14 + cells (monocytes and macrophages) in the CD4 + -and CD8 + -depleted cell fractions ( and , respectively) ruled out 3.9% ‫ע‬ 0.3% 3.1% ‫ע‬ 0.3% the loss of antigen-presenting cells engendering the above observation. Thus, NS3-stimulated IFN-g production by CD8
+ T cells appears to require CD4 + T cell help. Higher IFN-g levels correlate with absence of neurological deficits in convalescent patients. On the basis of the nature and severity of neurological sequelae in convalescent patients at the time of undertaking the study, they were assigned clinical scores, as described in Materials and Methods. A compilation of NS3-induced IFN-g data for the 32 patients revealed a remarkable and significant negative correlation between IFN-g levels and the severity of neurological impairment ( ; r p Ϫ0.9453 ; figure 5). Patients who had maximal neurological def-P ! .0001 icits also secreted the lowest, barely discernible levels of NS3-specific IFN-g (р35 pg/mL). Detectable but low-level IFN-g secretors (35-236 pg/mL) had less-severe manifestations. Those patients whose IFN-g levels were 1300 pg/mL uniquely showed near-total recovery from encephalitis with minimal neurological deficits. These results indicate that the ability of virus-specific T cells to produce IFN-g affects the clinical manifestations of JEV infection in humans. The presence of IFN-g-producing NS3-specific T cells in all healthy individuals living in JEV-endemic regions thus highlight vigorous Th1 responses to NS proteins such as NS3 as a probable critical determinant of long-term resistance to JEV.
DISCUSSION
Individuals from disease-endemic regions who, despite repeated exposure, experience asymptomatic infections that do not progress to disease are likely to have acquired natural resistance to the causative agent. Our comparison of virus-specific CMI parameters in a cohort of patients from a JEV-endemic area of this type with those in convalescent patients with JEV infection, a first attempt at which is represented by our study, should identify correlates of protective immunity for encephalitis caused by JEV as well as other flaviviruses. In our cohort, the NS3 protein was highly immunogenic and elicited T cells in 100% of the virusexposed subjects. In addition, use of the Tat-NS3 fusion protein facilitated the presentation of antigen on both the class I and II MHC molecules in vitro [31] , which permits the quantification of both CD8 + and CD4 + T cells. NS3, a highly conserved NS protein among the numerous isolates of JEV and other flaviviruses [32] , is recognized to contain flavivirus cross-reactive mouse and human T cell epitopes [9, 12, [33] [34] [35] [36] and can serve as target for human CMI responses across flavivirus infections. In fact, the impressive protection afforded by chimeric 17D yellow fever virus-JEV vaccine very likely emanates from crossreactive T cell help provided by yellow fever virus NS proteins to JEV E-specific neutralizing antibodies [37] .
Despite all individuals in the study having produced healthy levels of IFN-g to PHA and BCG, Th1 responses to NS3 were subdued in convalescent patients, an intriguing observation, considering the huge viral antigenic loads encountered in patients. Furthermore, only those patients whose NS3-specific T cells secreted at least a threshold level of IFN-g were spared from long-term neurological deficits after recovery from encephalitis. This implies that IFN-g is one of the important contributors to protective immunity against JEV. There are conflicting reports about the involvement of IFN-g in immunemediated protection in viral diseases of the central nervous system (CNS). A study reported that IL-12 suppresses protective immunity to JEV in mice through IFN-g [38] . Conversely, combined high levels of antibody-and antigen-specific Th1 lymphocytes in the brains of mice with flavivirus encephalitis were a critical factor for viral clearance [7, 8, 39] . Although it is extremely necessary to keep inflammatory responses under check in fulminant CNS infections, where the neurons are at risk of being destroyed by lytic immune mechanisms [40] , the antiviral cytokine IFN-g has been shown to inhibit viral replication by noncytolytic mechanisms [41] and to mediate noncytopathic clearance of virus from the CNS in the case of persistent lymphocytic choriomeningitis virus, Sindbis virus, mouse hepatitis virus, and vesicular stomatitis virus and in a transgenic mouse model of measles virus infection of neurons [41] [42] [43] [44] . In human dengue virus, HIV, and hepatitis B infections, a Th1 response had allied with milder form of disease and recovery from symptoms, whereas progression to exacerbated disease was predominantly characterized by a Th2-type response and a dearth of IFN-g [29, 45, 46] . Preexisting IFNg responses from T cells recognizing viruses of broad serotypes could potentially contribute to early viral clearance and reduced disease severity in dengue hemorrhagic fever [47] . Thus, IFNg that we detect in the peripheral immune system may act to curb viral intrusion into the brain and, in patients with encephalitis, also mediate noncytolytic protection in the CNS, which is an optimal strategy for viral clearance from tissues with little capacity for renewal. Consistent with the above hypothesis, we encountered only modest levels of perforin production by NS3-specific T cells, even in healthy JEV-immune individuals who nevertheless had vastly superior percentages of perforin-producing BCG-responsive T cells (data not shown).
That NS3-specific T cells in convalescent patients with JEV could respond by cell division while being selectively unable to produce IFN-g was puzzling-these T cells also did not produce detectable IL-4. The absence in patients of suitable HLA alleles required to present NS3-specific peptides was ruled out in view of the appreciable SI values and similar ethnic backgrounds of the healthy donors and patients. Attributing the higher levels of IFN-g in healthy donors to memory cells, as opposed to effectors in patients, the latter of which are known to produce lower levels per cell, appeared to be unlikely in light of the comparable mean fluorescence intensities of IFN-g-producing cells in the 2 groups. We are currently investigating the potential of NS3 or any other viral protein to stimulate IFN-g-suppressing cytokines such as IL-10 or transforming growth factor b in patients with JEV infection. The delayed kinetics of the appearance of effector T cells may also have contributed to the failure of patients in containing the virus. The nonavailability of pre-acutephase samples because of the extremely high ratio of subclinical infection to overt disease and the consequent inability to predict occurrence of encephalitis in cohorts in JEV-endemic areas makes an appraisal of this criterion extremely difficult.
Cellular antiviral immune responses arise with kinetics, consistent with the requirement for rapid viral elimination [48] . Besides, quick anamnestic antibody responses to the E protein driven by virus-specific CD4 + Th cells are believed to be the probable protective mechanism in a JEV challenge [49] . The development of functional CD8 + memory to achieve viral clearance has been recently recognized to have an obligatory requirement for CD4 + Th cells during priming [50] . Thus, the ability of a single protein such as NS3 to elicit both CD4 + and CD8 + T cells in healthy individuals who develop natural immunity to JEV underscores its importance as one of the targets of protective immunity mediated by T cells. A second role for NS3-specific T cells inferred from our data is to confer better prognosis even after the encephalitic phase of infection has been established, probably through an IFN-g-mediated noncytolytic clearance of the virus. Supplementation of the current E-based vaccine with conserved T cell antigens such as NS3 ought to enhance its long-term potency, render it less vulnerable to strain-specific variations by recruiting efficient T cell help, and confer on such a combination vaccine both prophylactic and therapeutic potential.
